our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
DEK-AFF2 fusion
i
Other names: DEK, DEK Proto-Oncogene, DEK Oncogene, Protein DEK, MRX2, Protein Ox19, FRAXE, Fragile X Mental Retardation 2, FMR2, OX19, FMR2P, Protein FMR-2, Fragile X Mental Retardation 2 Protein, AFF2, AF4/FMR2 Family Member 2, Fragile X E Mental Retardation Syndrome Protein
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
This study highlights that AFF2 IHC can be an invaluable surrogate marker to FISH in identifying DEK::AFF2 SCC in challenging cases to avoid misdiagnosis. Detailed clinical and pathologic data were collected to gain a better understanding of this emerging challenging entity. A literature review was performed to enrich our knowledge of DEK::AFF2 SCC.
2 months ago
Retrospective data • Review • Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • AFF2 (AF4/FMR2 family member 2)
Granular, cytoplasmic, or incomplete AFF staining should be considered as negative. In view of the rarity of DEK::AFF2 carcinomas, plasma cells and plasma cell neoplasms are potential for internal and surrogate external controls.
12 months ago
Retrospective data • Journal
|
AFF2 (AF4/FMR2 family member 2) • DEK (DEK Proto-Oncogene)
Our finding suggests that in nodal aspirates of patients with a history of sinonasal-type papillomas, especially those with prior malignant transformation or atypia, there should be consideration for the possibility of DEK::AFF2-related primary. When in doubt, DEK FISH of AFF2 immunohistochemistry should be performed for confirmation.
Sinonasal adenosquamous carcinoma is a somewhat heterogeneous tumor not infrequently arising ex papilloma and having various drivers including high- and low-risk HPV and rarely DEK::AFF2 fusion. The prognosis appears favorable when proper treatment is possible.
over 1 year ago
Journal
|
AFF2 (AF4/FMR2 family member 2) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
This tumor behaves aggressively involving adjacent vital structures, frequently recurs, and is inclined to develop lymph node and distant metastasis. This review aims to summarize the demographic, clinical, pathologic, immunophenotypic features, and pattern of molecular alterations as well as to discuss the differential diagnosis of DEK::AFF2 fusion carcinoma.